A novel CDK2/9 inhibitor CYC065 causes anaphase catastrophe and represses proliferation, tumorigenesis, and metastasis in aneuploid cancers

Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiuxia Liu, Cheng Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, Ethan Dmitrovsky

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Cyclin-dependent kinase 2 (CDK2) antagonism inhibits clustering of excessive centrosomes at mitosis, causing multipolar cell division and apoptotic death. This is called anaphase catastrophe. To establish induced anaphase catastrophe as a clinically tractable antineoplastic mechanism, induced anaphase catastrophe was explored in different aneuploid cancers after treatment with CYC065 (Cyclacel), a CDK2/9 inhibitor. Antineoplastic activity was studied in preclinical models. CYC065 treatment augmented anaphase catastrophe in diverse cancers including lymphoma, lung, colon, and pancreatic cancers, despite KRAS oncoprotein expression. Anaphase catastrophe was a broadly active antineoplastic mechanism. Reverse phase protein arrays (RPPAs) revealed that along with known CDK2/9 targets, focal adhesion kinase and Src phosphorylation that regulate metastasis were each repressed by CYC065 treatment. Intriguingly, CYC065 treatment decreased lung cancer metastases in in vivo murine models. CYC065 treatment also significantly reduced the rate of lung cancer growth in syngeneic murine and patient-derived xenograft (PDX) models independent of KRAS oncoprotein expression. Immunohistochemistry analysis of CYC065-treated lung cancer PDX models confirmed repression of proteins highlighted by RPPAs, implicating them as indicators of CYC065 antitumor response. Phospho-histone H3 staining detected anaphase catastrophe in CYC065-treated PDXs. Thus, induced anaphase catastrophe after CYC065 treatment can combat aneuploid cancers despite KRAS oncoprotein expression. These findings should guide future trials of this novel CDK2/9 inhibitor in the cancer clinic.

Original languageEnglish (US)
Pages (from-to)477-489
Number of pages13
JournalMolecular cancer therapeutics
Volume20
Issue number3
DOIs
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A novel CDK2/9 inhibitor CYC065 causes anaphase catastrophe and represses proliferation, tumorigenesis, and metastasis in aneuploid cancers'. Together they form a unique fingerprint.

Cite this